RESUMEN
Invasive fungal diseases (IFD) are difficult to treat and pose a significant threat to immunocompromised individuals. Current antifungal agents face limitations, including antifungal resistance and adverse effects. This review aims to give a comprehensive overview of emerging treatment strategies.Novel drugs in development are Ibrexafungerp, an orally available triterpenoid inhibiting glucan synthesis, and Rezafungin representing the echinocandins with extended half-life and improved tissue penetration, both recently licensed for certain indications. Fosmanogepix targets glycosylphosphatidylinositol biosynthesis, while Olorofim, an orotomide, inhibits fungal nucleic acid synthesis, both currently assessed in advanced clinical trials.Immunotherapeutic approaches include immune checkpoint inhibitors to enhance immune response in immunosuppressed individuals and fungal-specific allogeneic CAR-T cell therapy. For prophylactic purpose in high-risk populations to develop IFD, monoclonal antibodies against different virulence factors of Candida spp. have been discovered but are not yet seen in clinical trials. Vaccines against distinct fungal antigens as well as pan fungal vaccines to prevent IFD are under development in preclinical stages, notably for Candida spp., Cryptococcus spp., and Aspergillus spp., however, their clinical value is still discussed.In summary, major advances to treat IFD have been observed, but challenges for their establishment in the clinical routine persist.
Asunto(s)
Antifúngicos , Infecciones Fúngicas Invasoras , Humanos , Infecciones Fúngicas Invasoras/prevención & control , Infecciones Fúngicas Invasoras/tratamiento farmacológico , Antifúngicos/uso terapéutico , Vacunas Fúngicas/uso terapéutico , Vacunas Fúngicas/inmunología , Inmunoterapia/métodos , Terapias en InvestigaciónRESUMEN
Fungi are an integral part of the mammalian microbiota colonizing most if not all mucosal surfaces and the skin. Maintaining stable colonization on these surfaces is critical for preventing fungal dysbiosis and infection, which in some cases can lead to life threatening consequences. The epithelial barriers are protected by T cells and additional controlling immune mechanisms. Noncirculating memory T cells that reside stably in barrier tissues play an important role for host protection from commensals and recurrent pathogens due to their fast response and local activity, which provides them a strategic advantage. So far, only a few specific examples of tissue resident memory T cells (TRMs) that act against fungi have been reported. This review provides an overview of the characteristics and functional attributes of TRMs that have been established based on human and mouse studies with various microbes. It highlights what is currently known about fungi specific TRMs mediating immunosurveillance, how they have been targeted in preclinical vaccination approaches and how they can promote immunopathology, if not controlled. A better appreciation of the host protective and damaging roles of TRMs might accelerate the development of novel tissue specific preventive strategies against fungal infections and fungi-driven immunopathologies.
Asunto(s)
Hongos/inmunología , Memoria Inmunológica , Células T de Memoria/inmunología , Micosis/inmunología , Animales , Vacunas Fúngicas/inmunología , Vacunas Fúngicas/uso terapéutico , Hongos/patogenicidad , Interacciones Huésped-Patógeno , Humanos , Células T de Memoria/metabolismo , Micosis/metabolismo , Micosis/microbiología , Micosis/prevención & control , FenotipoRESUMEN
Sporotrichosis is an emergent subcutaneous mycosis of humans and some animals caused by dimorphic fungi of the genus Sporothrix. The disease occurs worldwide but is endemic or hyperendemic in tropical and subtropical areas. The epidemiology of the disease is changing dramatically, and it is now considered an important zoonosis with high morbidity rates, principally in Brazil, and an opportunistic infection in immunocompromised patients. Due to the limited options currently available to treat invasive fungal infections, including sporotrichosis, and the emergence of drug resistance and toxicity, the development of anti-Sporothrix vaccines has become an area of great interest. This work provides a brief analysis of the feasibility of the development of prophylactic and therapeutic vaccines against sporotrichosis, the main advances achieved to date, future challenges and prospects.
Asunto(s)
Antígenos Fúngicos/inmunología , Vacunas Fúngicas/uso terapéutico , Sporothrix/inmunología , Esporotricosis/prevención & control , Esporotricosis/terapia , Adyuvantes Inmunológicos/administración & dosificación , Adyuvantes Inmunológicos/uso terapéutico , Animales , Vacunas Fúngicas/administración & dosificación , Vacunas Fúngicas/inmunología , Humanos , Inmunoterapia , Profilaxis Pre-Exposición , Sporothrix/efectos de los fármacos , Esporotricosis/diagnóstico , Esporotricosis/inmunologíaRESUMEN
NDV-3A, a novel fungal vaccine undergoing clinical trials, contains a recombinant version of the Candida albicans rAls3 N-terminus protein (rAls3p-N) in aluminum hydroxide. In a Phase 1b/2a clinical trial, NDV-3A protected women from recurrent vulvovaginal candidiasis. Here, we reveal that active immunization in mice with NDV-3A induces high titers of anti-rAls3p-N antibodies that interfere with C. albicans ability to adhere to and invade endothelial cells, and form biofilm in vitro. Anti-rAls3p-N antibodies also significantly inhibit yeast dispersal from the hyphal layers of biofilms. Compared to placebo, NDV-3A vaccination inhibited C. albicans dissemination to kidneys and prevented colonization of central venous catheters in mice. Overall, these preclinical studies suggest that NDV-3A may serve as an immunotherapeutic strategy for prevention of infections on indwelling medical devices.
Asunto(s)
Anticuerpos Antifúngicos/farmacología , Proteínas Fúngicas/inmunología , Vacunas Fúngicas/uso terapéutico , Vacunación/métodos , Animales , Anticuerpos Antifúngicos/inmunología , Biopelículas/efectos de los fármacos , Candida albicans/efectos de los fármacos , Candida albicans/inmunología , Adhesión Celular/efectos de los fármacos , Catéteres Venosos Centrales/microbiología , Vacunas Fúngicas/farmacología , Humanos , Control de Infecciones , Ratones , Proteínas RecombinantesRESUMEN
Fungal infections include a wide range of opportunistic and invasive diseases. Two of four major fatal diseases in patients with human immunodeficiency virus (HIV) infection are related to the fungal infections, cryptococcosis, and pneumocystosis. Disseminated candidiasis and different clinical forms of aspergillosis annually impose expensive medical costs to governments and hospitalized patients and ultimately lead to high mortality rates. Therefore, urgent implementations are necessary to prevent the expansion of these diseases. Designing an effective vaccine is one of the most important approaches in this field. So far, numerous efforts have been carried out in developing an effective vaccine against fungal infections. Some of these challenges engaged in different stages of clinical trials but none of them could be approved by the United States Food and Drug Administration (FDA). Here, in addition to have a comprehensive overview on the data from studied vaccine programs, we will discuss the immunology response against fungal infections. Moreover, it will be attempted to clarify the underlying immune mechanisms of vaccines targeting different fungal infections that are crucial for designing an effective vaccination strategy.
Asunto(s)
Antifúngicos/uso terapéutico , Vacunas Fúngicas/uso terapéutico , Micosis/inmunología , Micosis/prevención & control , Animales , Antifúngicos/farmacología , Vacunas Fúngicas/farmacología , Humanos , Inmunidad Innata/efectos de los fármacos , Inmunidad Innata/inmunologíaRESUMEN
Candidemia is a bloodstream fungal infection caused by Candida species and is most commonly observed in hospitalized patients. Even with proper antifungal drug treatment, mortality rates remain high at 40-50%. Therefore, prophylactic or preemptive antifungal medications are currently recommended in order to prevent infections in high-risk patients. Moreover, the majority of women experience at least one episode of vulvovaginal candidiasis (VVC) throughout their lifetime and many of them suffer from recurrent VVC (RVVC) with frequent relapses for the rest of their lives. While there currently exists no definitive cure, the only available treatment for RVVC is again represented by antifungal drug therapy. However, due to the limited number of existing antifungal drugs, their associated side effects and the increasing occurrence of drug resistance, other approaches are greatly needed. An obvious prevention measure for candidemia or RVVC relapse would be to immunize at-risk patients with a vaccine effective against Candida infections. In spite of the advanced and proven techniques successfully applied to the development of antibacterial or antiviral vaccines, however, no antifungal vaccine is still available on the market. In this review, we first summarize various efforts to date in the development of anti-Candida vaccines, highlighting advantages and disadvantages of each strategy. We next unfold and discuss general hurdles encountered along these efforts, such as the existence of large genomic variation and phenotypic plasticity across Candida strains and species, and the difficulty in mounting protective immune responses in immunocompromised or immunosuppressed patients. Lastly, we review the concept of "trained immunity" and discuss how induction of this rapid and nonspecific immune response may potentially open new and alternative preventive strategies against opportunistic infections by Candida species and potentially other pathogens.
Asunto(s)
Candida/inmunología , Candidemia/prevención & control , Candidiasis Vulvovaginal/prevención & control , Vacunas Fúngicas/inmunología , Infecciones Oportunistas/prevención & control , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Candida/efectos de los fármacos , Candidemia/tratamiento farmacológico , Candidemia/inmunología , Candidemia/microbiología , Candidiasis Vulvovaginal/tratamiento farmacológico , Candidiasis Vulvovaginal/inmunología , Candidiasis Vulvovaginal/microbiología , Farmacorresistencia Fúngica/inmunología , Femenino , Vacunas Fúngicas/uso terapéutico , Humanos , Huésped Inmunocomprometido/inmunología , Infecciones Oportunistas/tratamiento farmacológico , Infecciones Oportunistas/inmunología , Infecciones Oportunistas/microbiología , Resultado del TratamientoRESUMEN
Background: Recurrent vulvovaginal candidiasis (RVVC) is a problematic form of mucosal Candida infection, characterized by repeated episodes per year. Candida albicans is the most common cause of RVVC. Currently, there are no immunotherapeutic treatments for RVVC. Methods: This exploratory randomized, double-blind, placebo-controlled trial evaluated an immunotherapeutic vaccine (NDV-3A) containing a recombinant C. albicans adhesin/invasin protein for prevention of RVVC. Results: The study in 188 women with RVVC (n = 178 evaluable) showed that 1 intramuscular dose of NDV-3A was safe and generated rapid and robust B- and T-cell immune responses. Post hoc exploratory analyses revealed a statistically significant increase in the percentage of symptom-free patients at 12 months after vaccination (42% vaccinated vs 22% placebo; P = .03) and a doubling in median time to first symptomatic episode (210 days vaccinated vs 105 days placebo) for the subset of patients aged <40 years (n = 137). The analysis of evaluable patients, which combined patients aged <40 years (77%) and ≥40 years (23%), trended toward a positive impact of NDV-3A versus placebo (P = .099). Conclusions: In this unprecedented study of the effectiveness of a fungal vaccine in humans, NDV-3A administered to women with RVVC was safe and highly immunogenic and reduced the frequency of symptomatic episodes of vulvovaginal candidiasis for up to 12 months in women aged <40 years. These results support further development of NDV-3A vaccine and provide guidance for meaningful clinical endpoints for immunotherapeutic management of RVVC. Clinical Trials Registration: NCT01926028.
Asunto(s)
Candidiasis Vulvovaginal/terapia , Proteínas Fúngicas/uso terapéutico , Vacunas Fúngicas/uso terapéutico , Inmunoterapia , Adolescente , Adulto , Linfocitos B/inmunología , Candida albicans/efectos de los fármacos , Candidiasis Vulvovaginal/inmunología , Método Doble Ciego , Femenino , Vacunas Fúngicas/efectos adversos , Humanos , Inmunogenicidad Vacunal , Inyecciones Intramusculares , Persona de Mediana Edad , Recurrencia , Linfocitos T/inmunología , Adulto JovenRESUMEN
Paracoccidioidomycosis (PCM) represents the most frequent systemic mycosis in Latin American. The disease is caused by the pathogenic thermally dimorphic fungus Paracoccidioides brasiliensis, and is initially characterized by pulmonary lesions, which can subsequently disseminate to other organs, resulting in secondary injuries. Although its high incidence, there is no commercially available vaccine against fungal diseases. A novel strategy, using Saccharomyces cerevisiae yeast as a vehicle for immunization against PCM, was recently successfully described. Herein, we describe strategies for the construction of the suitable S. cerevisiae vaccine, and protocols of administration and evaluation of the efficacy of the vaccine against experimental PCM.
Asunto(s)
Antígenos Fúngicos/administración & dosificación , Antígenos Fúngicos/genética , Proteínas Fúngicas/genética , Proteínas Fúngicas/inmunología , Vacunas Fúngicas/inmunología , Glicoproteínas/genética , Glicoproteínas/inmunología , Paracoccidioidomicosis/inmunología , Animales , Antígenos Fúngicos/inmunología , Clonación Molecular , Citocinas/metabolismo , Vacunas Fúngicas/uso terapéutico , Expresión Génica , Inmunización , Inmunoterapia , Ratones , Sistemas de Lectura Abierta , Paracoccidioidomicosis/microbiología , Paracoccidioidomicosis/prevención & control , Paracoccidioidomicosis/terapia , Proteínas Recombinantes/genética , Proteínas Recombinantes/inmunologíaRESUMEN
Fungal infection is an important clinical problem for patients with immune deficiency or immunosuppression. With deadly fungus infection case increasing, the development of antifungal vaccine attracts the attention of researchers. Dendritic cell (DC) is the unique antigen presenting cell (APC) to trigger the antifungal immune reaction, and recent studies indicate that the targeted vaccination strategy based on DC have prospective antifungal potentials. In this paper, we review the antifungal immunity mechanism and recent development of the targeted DC antifungal strategy.
Asunto(s)
Células Dendríticas , Vacunas Fúngicas/uso terapéutico , Micosis/terapia , Humanos , Micosis/inmunologíaRESUMEN
Fungal infections have skyrocketed in immune-compromised patients lacking CD4+ T cells, underscoring the need for vaccine prevention. An understanding of the elements that promote vaccine immunity in this setting is essential. We previously demonstrated that vaccine-induced IL-17A+ CD8+ T cells (Tc17) are required for resistance against lethal fungal pneumonia in CD4+ T cell-deficient hosts, whereas the individual type I cytokines IFN-γ, TNF-α and GM-CSF, are dispensable. Here, we report that T cell-intrinsic MyD88 signals are crucial for these Tc17 cell responses and vaccine immunity against lethal fungal pneumonia in mice. In contrast, IFN-γ+ CD8+ cell (Tc1) responses are largely normal in the absence of intrinsic MyD88 signaling in CD8+ T cells. The poor accumulation of MyD88-deficient Tc17 cells was not linked to an early onset of contraction, nor to accelerated cell death or diminished expression of anti-apoptotic molecules Bcl-2 or Bcl-xL. Instead, intrinsic MyD88 was required to sustain the proliferation of Tc17 cells through the activation of mTOR via Akt1. Moreover, intrinsic IL-1R and TLR2, but not IL-18R, were required for MyD88 dependent Tc17 responses. Our data identify unappreciated targets for augmenting adaptive immunity against fungi. Our findings have implications for designing fungal vaccines and immune-based therapies in immune-compromised patients.
Asunto(s)
Blastomyces/inmunología , Blastomicosis/prevención & control , Vacunas Fúngicas/uso terapéutico , Memoria Inmunológica , Neumonía/prevención & control , Linfocitos T Citotóxicos/inmunología , Células Th17/inmunología , Animales , Blastomyces/fisiología , Blastomicosis/inmunología , Blastomicosis/metabolismo , Blastomicosis/microbiología , Proliferación Celular , Células Cultivadas , Depleción Linfocítica , Ratones , Ratones Congénicos , Ratones Endogámicos C57BL , Ratones Noqueados , Ratones Transgénicos , Factor 88 de Diferenciación Mieloide/metabolismo , Neumonía/inmunología , Neumonía/metabolismo , Neumonía/microbiología , Proteínas Proto-Oncogénicas c-akt/metabolismo , Receptores Tipo I de Interleucina-1/metabolismo , Transducción de Señal , Linfocitos T Citotóxicos/metabolismo , Linfocitos T Citotóxicos/microbiología , Linfocitos T Citotóxicos/patología , Serina-Treonina Quinasas TOR/metabolismo , Células Th17/metabolismo , Células Th17/microbiología , Células Th17/patología , Receptor Toll-Like 2/metabolismoAsunto(s)
Sporothrix/fisiología , Esporotricosis/microbiología , Esporotricosis/patología , Animales , Antifúngicos/uso terapéutico , Vacunas Fúngicas/uso terapéutico , Humanos , Sporothrix/inmunología , Sporothrix/patogenicidad , Esporotricosis/epidemiología , Esporotricosis/prevención & control , Zoonosis/epidemiología , Zoonosis/microbiología , Zoonosis/transmisiónRESUMEN
Concomitant with the increased prevalence of immunocompromised persons, invasive fungal infections have become considerably more frequent in the last 50 years. High mortality rates caused by invasive mycoses and high morbidity because of intractable mucosal infections have created an unmet need for innovative prophylactic and therapeutic strategies against fungal pathogens. Several immunotherapeutics and vaccines are in development to address this need, although one has yet to reach the clinic. This review focuses on past and current immunotherapeutic and vaccine strategies being tested to either prevent or treat fungal infections, as well as the challenges associated with their development.
Asunto(s)
Vacunas Fúngicas/uso terapéutico , Micosis/terapia , Vacunas Fúngicas/inmunología , Humanos , Inmunoterapia/métodos , Micosis/prevención & control , Vacunas Atenuadas/uso terapéutico , Vacunas Conjugadas/uso terapéutico , Vacunas de Productos Inactivados/uso terapéutico , Vacunas Sintéticas/uso terapéuticoRESUMEN
Vaccines against fungal diseases are gaining attention because of their growing impact on modern medicine. Development of these vaccines should incorporate immunological tools that integrate with or replace chemotherapy to minimize antibiotic use and consequent resistance. In this review, we evaluate the current developmental status of fungal vaccines against coccidioidomycosis. There is a need for a vaccine that sufficiently prevents disease, without eradicating the fungus, by neutralizing adhesions and enzymes or other low penetrance virulence traits.
Asunto(s)
Coccidioides/inmunología , Coccidioidomicosis/prevención & control , Vacunas Fúngicas/uso terapéutico , Animales , Coccidioides/patogenicidad , Coccidioidomicosis/inmunología , Coccidioidomicosis/microbiología , Humanos , VirulenciaAsunto(s)
Vacunas Fúngicas/efectos adversos , Fungemia/etiología , Enfermedades del Prematuro/etiología , Probióticos/efectos adversos , Saccharomyces/aislamiento & purificación , Antifúngicos/uso terapéutico , Apnea/etiología , Candidemia/diagnóstico , Infecciones Relacionadas con Catéteres , Diagnóstico Diferencial , Contaminación de Equipos , Fluconazol/uso terapéutico , Vacunas Fúngicas/uso terapéutico , Fungemia/diagnóstico , Fungemia/tratamiento farmacológico , Fungemia/microbiología , Fungemia/transmisión , Humanos , Recien Nacido con Peso al Nacer Extremadamente Bajo , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro/tratamiento farmacológico , Enfermedades del Prematuro/microbiología , Masculino , Nutrición Parenteral/instrumentación , Probióticos/uso terapéutico , Saccharomyces/efectos de los fármacosRESUMEN
Many amphibians have declined globally due to introduction of the pathogenic fungus Batrachochytrium dendrobatidis (Bd). Hundreds of species, many in well-protected habitats, remain as small populations at risk of extinction. Currently the only proven conservation strategy is to maintain species in captivity to be reintroduced at a later date. However, methods to abate the disease in the wild are urgently needed so that reintroduced and wild animals can survive in the presence of Bd. Vaccination has been widely suggested as a potential strategy to improve survival. We used captive-bred offspring of critically endangered booroolong frogs (Litoria booroolongensis) to test if vaccination in the form of prior infection improves survival following re exposure. We infected frogs with a local Bd isolate, cleared infection after 30 days (d) using itraconazole just prior to the onset of clinical signs, and then re-exposed animals to Bd at 110 d. We found prior exposure had no effect on survival or infection intensities, clearly showing that real infections do not stimulate a protective adaptive immune response in this species. This result supports recent studies suggesting Bd may evade or suppress host immune functions. Our results suggest vaccination is unlikely to be useful in mitigating chytridiomycosis. However, survival of some individuals from all experimental groups indicates existence of protective innate immunity. Understanding and promoting this innate resistance holds potential for enabling species recovery.
Asunto(s)
Anfibios/microbiología , Quitridiomicetos/inmunología , Quitridiomicetos/patogenicidad , Animales , Antifúngicos/uso terapéutico , Vacunas Fúngicas/uso terapéutico , Itraconazol/uso terapéutico , VacunaciónRESUMEN
Vaccines against fungal diseases are gaining attention because of their growing impact on modern medicine. Development of these vaccines should incorporate immunological tools that integrate with or replace chemotherapy to minimize antibiotic use and consequent resistance. In this review, we evaluate the current developmental status of fungal vaccines against coccidioidomycosis. There is a need for a vaccine that sufficiently prevents disease, without eradicating the fungus, by neutralizing adhesions and enzymes or other low penetrance virulence traits.
Asunto(s)
Animales , Humanos , Coccidioides/inmunología , Coccidioidomicosis/inmunología , Vacunas Fúngicas/uso terapéutico , VirulenciaRESUMEN
Invasive fungal diseases are increasingly important opportunistic infections that are intimately linked to immune-suppression in the context of cytotoxic treatment of neoplastic diseases, stem cell and solid-organ transplantation, and primary immune deficiencies. Mortality rates remain high despite the availability of novel antifungals that are both safe and highly active in vitro, suggesting that clinical outcomes may be improved through modulation of host immunity. Ongoing advances in our knowledge of fungal-host interactions facilitate rational design of novel immunotherapeutics. Thus, antifungal immunotherapy now includes age-old interventions such as granulocyte and immunoglobulin transfusions, as well as promising experimental techniques such as antifungal vaccines and adoptive immunotherapy. To realize the potential of these rapidly evolving technologies, transition from the bench to clinical-phase studies must occur at a more rapid pace.
Asunto(s)
Síndromes de Inmunodeficiencia/terapia , Factores Inmunológicos/uso terapéutico , Inmunosupresores/efectos adversos , Inmunoterapia Adoptiva/métodos , Micosis/terapia , Neoplasias/tratamiento farmacológico , Infecciones Oportunistas/terapia , Animales , Vacunas Fúngicas/uso terapéutico , Granulocitos/trasplante , Interacciones Huésped-Patógeno , Humanos , Huésped Inmunocomprometido , Inmunoglobulinas Intravenosas/uso terapéutico , Síndromes de Inmunodeficiencia/etiología , Inmunoterapia Adoptiva/tendencias , Terapia Molecular Dirigida , Micosis/etiología , Micosis/prevención & control , Infecciones Oportunistas/etiología , Infecciones Oportunistas/prevención & control , Trasplante de ÓrganosRESUMEN
Diseases caused by fungi are increasingly impacting the health of the human population and now account for a large fraction of infectious disease complications in individuals with impaired immunity or breached tissue defenses. Antifungal therapy is often of limited effectiveness in these patients, resulting into treatment failures, chronic infections and unacceptable rates of mortality, morbidity and their associated costs. Consequently there is a real medical need for new treatments and preventive measures to combat fungal diseases and, toward this goal, safe and efficacious vaccines would constitute major progress. After decades of complacency and neglect of this critically important field of research, remarkable progress has been made in recent years. A number of highly immunogenic and protective vaccine formulations in preclinical setting have been developed, and at least two have undergone Phase 1 clinical trials as preventive and/or therapeutic tools against candidiasis.
Asunto(s)
Vacunas Fúngicas , Micosis/inmunología , Micosis/prevención & control , Aspergilosis/inmunología , Aspergilosis/prevención & control , Candidiasis Vulvovaginal/inmunología , Candidiasis Vulvovaginal/prevención & control , Criptococosis/inmunología , Criptococosis/prevención & control , Femenino , Vacunas Fúngicas/administración & dosificación , Vacunas Fúngicas/inmunología , Vacunas Fúngicas/uso terapéutico , Hongos/inmunología , HumanosRESUMEN
Aspergillus fumigatus is a model fungal pathogen and a common cause of severe infections and diseases. CD8⺠T cells are present in the human and murine T-cell repertoire to the fungus. However, CD8⺠T-cell function in infection and the molecular mechanisms that control their priming and differentiation into effector and memory cells in vivo remain elusive. In the present study, we report that both CD4⺠and CD8⺠T cells mediate protective memory responses to the fungus contingent on the nature of the fungal vaccine. Mechanistically, class I MHC-restricted, CD8⺠memory T cells were activated through TLR3 sensing of fungal RNA by cross-presenting dendritic cells. Genetic deficiency of TLR3 was associated with susceptibility to aspergillosis and concomitant failure to activate memory-protective CD8⺠T cells both in mice and in patients receiving stem-cell transplantations. Therefore, TLR3 essentially promotes antifungal memory CD8⺠T-cell responses and its deficiency is a novel susceptibility factor for aspergillosis in high-risk patients.
Asunto(s)
Aspergilosis/inmunología , Aspergillus fumigatus/inmunología , Linfocitos T CD8-positivos/inmunología , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Huésped Inmunocomprometido , Memoria Inmunológica , Receptor Toll-Like 3/metabolismo , Animales , Presentación de Antígeno , Antígenos Fúngicos/uso terapéutico , Aspergilosis/genética , Aspergilosis/prevención & control , Linfocitos T CD8-positivos/citología , Linfocitos T CD8-positivos/metabolismo , Células Cultivadas , Estudios de Cohortes , Células Dendríticas/citología , Células Dendríticas/inmunología , Células Dendríticas/metabolismo , Susceptibilidad a Enfermedades , Femenino , Vacunas Fúngicas/uso terapéutico , Humanos , Activación de Linfocitos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Polimorfismo de Nucleótido Simple , Organismos Libres de Patógenos Específicos , Receptor Toll-Like 3/genéticaRESUMEN
Candidiasis is the fourth most common bloodstream infection in hospitalized patients in the United States. Moreover, the mortality rate from Candida infections remains high, even after treatment with antifungal therapy. Vaccination would be a promising strategy for prevention of invasive fungal infections. In order to examine the main trends in anticandidal vaccine patenting activity, we conducted an analysis for anticandidal vaccine patents. We find 190 issued patent and 940 patent application documents containing the keywords Candida and vaccine within claims in the USA. Candida vaccines development, as evidenced by the numbers of issued patents, has decreased since the year 2002. Furthermore, the number of patent applications in Candida vaccines may indicate the strength of engaged resources were also in the status of stagnation during 2005-2007 and even a decline in 2008. Academic and nonprofit research institutions not only account for a large share of Candida vaccines patents but also apply for patents continually. Based on this analysis, the strength of Candida vaccines resources seems to remain stagnant in recent years due to patent prosecution or technical barrier in the filed of Candida vaccines. Therefore, we consider that Candida vaccines technology to still be under development and the researchers are still looking for scientific breakthrough in the filed.